Anonymous
Guest
Anonymous
Guest
Merck's change for the worse began around 1994 when the corporation's board of directors stumbled badly in finding a successor to Dr. Vagelos. Many mid and senior level managers took advantage of early retirements at that time. It's been one long downhill slide ever since then. As for becoming another "Pfizer", this actually began around 1997 when Gerry Gallivan would voice this as Merck's new strategy for meeting the challenges Merck had never faced before. Lipitor was the new king of the statin franchise after having quickly and handily kicking Merck's Mevacor/Zocor from their lofty dominance of the market. Merck's solution to this new uncomfortable position: BECOME LIKE PFIZER. And all of us still here at Merck know only too well how that has worked out..... Turnover of employees at all levels has been common ever since and Merck's admirability has faded into the distant past now. All the executive clowns who decided to try and make Merck just like Pfizer are long gone, too. Unfortunately, their negative influence destroyed what had been a great pharmaceutical company and employer and those of us left continue to suffer their toxic legacy.
100% spot on...excellent assessment...